Remove Investments Remove Pharmaceutical Remove Valuation
article thumbnail

Local pharma companies queue up for JB Chemicals & Pharmaceuticals

CFO News

Mankind Pharma, Dr Reddy's Laboratories, and Torrent Pharma are interested in acquiring JB Chemicals & Pharmaceuticals from KKR. KKR's investment arm, TAU Investment, owns 53.78% in JB Chemicals, worth Rs 14,020 crore. JB Chemicals has made four acquisitions in the last four years, investing $200 million.

article thumbnail

The Difference Makers: Key Person(s) Valuation

Musings on Markets

Of course, and with small businesses, especially those built around personal services (a doctor or plumber’s practice), it is part of the valuation process, where the key person is valued or at least priced and incorporated into valuation. To estimate key person value, there are three general approaches: 1.

Valuation 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Catastrophic Risk: Investing and Business Implications

Musings on Markets

In the context of valuing companies, and sharing those valuations, I do get suggestions from readers on companies that I should value next. Applications : When valuing businesses in developed markets, we tend to assume that these businesses have insured themselves against most catastrophic risks and ignore them in valuation consequently.

article thumbnail

Six Flags, Rivian, Bumble, Coinbase, Dutch Bros and more

CFO News Room

related investing news. It missed top and bottom line expectations when reporting quarterly results, but announced an agreement with the investment firm H Partners that raised the cap on the firm’s stake to 19.9% AstraZeneca – The pharmaceutical company added 6.6% Coinbase – The cryptocurrency exchange was up 10.7%

article thumbnail

Chinese Study highlights limitations on IAS 38, accounting for intangible assets

CFO Talks

The authors argue that the standard is not suitable for industries that rely on long-term innovation cycles, where R&D investment is essential. As a result, much of the R&D investment is expensed upfront , which creates a mismatch between costs and the revenues they eventually generate.

article thumbnail

Musings on Markets: META Lesson 3: Tell me a story!

CFO News Room

In fact, I concluded the post by arguing that investors in Facebook were pricing in their belief that the billions of dollars the company had invested in the Metaverse would be wasted, and argued that Facebook faced some of the blame, for not telling a compelling story to back the investment.

Marketing 130
article thumbnail

Just do it! Brand Name Lessons from Nike'sTroubles!

Musings on Markets

The pharmaceutical companies have some brand name value, but a bigger portion of their value added comes from the protection against competition they get from owning patents. for a product with no differentiating features. billion, with much of that value coming from its pre-tax operating margin of 29.73%. Pepper etc.),